WO2001032197A3 - Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders - Google Patents

Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders Download PDF

Info

Publication number
WO2001032197A3
WO2001032197A3 PCT/US2000/026272 US0026272W WO0132197A3 WO 2001032197 A3 WO2001032197 A3 WO 2001032197A3 US 0026272 W US0026272 W US 0026272W WO 0132197 A3 WO0132197 A3 WO 0132197A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pdgf
related protein
musculoskeletal disorders
treat musculoskeletal
Prior art date
Application number
PCT/US2000/026272
Other languages
French (fr)
Other versions
WO2001032197A2 (en
Inventor
Janet Mary Hock
Songqing Na
Lisa Janine Hammond
Alexei Kharitonenkov
Venkatesh Krishnan
Gerald Wayne Becker
Original Assignee
Lilly Co Eli
Janet Mary Hock
Songqing Na
Lisa Janine Hammond
Alexei Kharitonenkov
Venkatesh Krishnan
Gerald Wayne Becker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Janet Mary Hock, Songqing Na, Lisa Janine Hammond, Alexei Kharitonenkov, Venkatesh Krishnan, Gerald Wayne Becker filed Critical Lilly Co Eli
Priority to AU14306/01A priority Critical patent/AU1430601A/en
Publication of WO2001032197A2 publication Critical patent/WO2001032197A2/en
Publication of WO2001032197A3 publication Critical patent/WO2001032197A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]

Abstract

The invention provides compositions and methods for treating osteopenia, osteoporosis, arthritis, sarcopenia, peridontal disease or promoting bone growth comprising the administration of a therapeutically effective amount of LP8, a fragment thereof, an analog thereof, and/or an antagonist or agonist thereof.
PCT/US2000/026272 1999-11-02 2000-10-24 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders WO2001032197A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14306/01A AU1430601A (en) 1999-11-02 2000-10-24 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16320399P 1999-11-02 1999-11-02
US16320499P 1999-11-02 1999-11-02
US16305699P 1999-11-02 1999-11-02
US60/163,203 1999-11-02
US60/163,056 1999-11-02
US60/163,204 1999-11-02

Publications (2)

Publication Number Publication Date
WO2001032197A2 WO2001032197A2 (en) 2001-05-10
WO2001032197A3 true WO2001032197A3 (en) 2002-03-07

Family

ID=27388828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026272 WO2001032197A2 (en) 1999-11-02 2000-10-24 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders

Country Status (2)

Country Link
AU (1) AU1430601A (en)
WO (1) WO2001032197A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663870B2 (en) 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
EP1991282B1 (en) 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
JP5484047B2 (en) 2006-06-30 2014-05-07 バイオミメティック セラピューティクス， エルエルシー PDGF-biomatrix composition and method for treating rotator cuff injury
NZ601559A (en) 2010-02-22 2014-10-31 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376636A (en) * 1991-03-12 1994-12-27 Creative Biomolecules, Inc. Method for promoting tissue repair and regeneration using PDGF and glucocorticoids
WO1995028950A1 (en) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration
US5533836A (en) * 1993-03-29 1996-07-09 Zymogenetics, Inc. Compositions and methods for stimulating the growth of osteoblasts
WO1999047677A2 (en) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
WO2000037641A2 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-x
WO2000059940A2 (en) * 1999-04-06 2000-10-12 Eli Lilly And Company Platelet-derived growth factor related gene and protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376636A (en) * 1991-03-12 1994-12-27 Creative Biomolecules, Inc. Method for promoting tissue repair and regeneration using PDGF and glucocorticoids
US5533836A (en) * 1993-03-29 1996-07-09 Zymogenetics, Inc. Compositions and methods for stimulating the growth of osteoblasts
WO1995028950A1 (en) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration
WO1999047677A2 (en) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
WO2000037641A2 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-x
WO2000059940A2 (en) * 1999-04-06 2000-10-12 Eli Lilly And Company Platelet-derived growth factor related gene and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMADA T ET AL: "A NOVEL GENE DERIVED FROM DEVELOPING SPINAL CORDS, SCDGF, IS A UNIQUE MEMBER OF THE PDGF/VEGF FAMILY", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 475, no. 2, 2000, pages 97 - 102, XP000952876, ISSN: 0014-5793 *
LI X ET AL: "PDGF-C IS A NEW PROTEASE-ACTIVATED LIGAND FOR THE PDGF ALPHA-RECEPTOR", NATURE CELL BIOLOGY,MACMILLAN PUBLISHERS,GB, vol. 2, no. 5, May 2000 (2000-05-01), pages 302 - 309, XP000956444, ISSN: 1465-7392 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries

Also Published As

Publication number Publication date
WO2001032197A2 (en) 2001-05-10
AU1430601A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
FR06C0032I2 (en) PROTEIN FORMULATIONS
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
ATE450269T1 (en) PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES
HUP0202319A2 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
HK1078466A1 (en) Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance
WO2004016256A3 (en) AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
PT2009025E (en) Method of inhibiting osteoclast activity
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
WO2001032197A3 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
BR0015781A (en) Pharmaceutical composition for treatment of diseases associated with decreased bone mass
MY130725A (en) Composition and method for treating allergic diseases
DE60006948T2 (en) ANTAGONISM OF THE ESTROGEN RECEPTOR BETA AND BONE DISEASES
WO2001089450A3 (en) Treating musculoskeletal disorders using lp85 and analogs thereof
EP1400810A3 (en) Estrogen receptors and bone disease
IL152668A0 (en) Pharmaceutical compositions comprising vip-related peptides for the treatment of sexual disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP